Companies › KNSA

KINIKSA PHARMACEUTICALS INTL (KNSA)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001730430 · EDGAR filings · Updated 2026-07-28

KINIKSA PHARMACEUTICALS INTL (KNSA) has reported institutional ownership of 59.3%, with 227 institutional managers holding positions valued at $2.18B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Filings this week (2)

• 2026-07-28 — Current report (8-K) filed
• 2026-07-28 — Quarterly report (10-Q) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-06 — Insider transaction reported (Form 4)
• 2026-07-06 — Initial insider ownership filed (Form 3)
• 2026-06-02 — Insider transaction reported (Form 4)
• 2026-06-02 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, KINIKSA PHARMACEUTICALS INTL has 227 institutional holders and institutional ownership of 59.3%.

Insider activity

Insiders reported 271 transactions (0 buys, 80 sells) across 13 reporting insiders, with a net reported value of −$60.3M.

Data flags from SEC filings

Related companies

VIRIDIAN THERAPEUTICS INC (VRDN) · KODIAK SCIENCES (KOD) · ALUMIS INC (ALMS) · NEOGEN CORPORATION (NEOG) · AGIOS PHARMACEUTICALS INC (AGIO) · ADAPTIVE BIOTECHNOLOGIES COR (ADPT)